Table 2.
Relevant clinical data of the patients with CML recruited for this study.
| Patient’ Code |
Gender (M/F) | Age at Diagnosis (Years) |
Sokal Risk | CML Phase: Chronic Accelerated Blast |
Hematological Remission (Y/N) | Cytogenetic Remission (Y/N) | Molecular Response (Log) | Last TKI | Time on Treatment with Last TKI (Months) |
Time on TFR (Months) |
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| New CML diagnosis | 1 | F | 44 | Low | Chronic | N/A | N/A | N/A | - | - | - |
| 2 | M | 56 | High | Chronic | N/A | N/A | N/A | - | - | - | |
| 3 | F | 45 | Low | Chronic | N/A | N/A | N/A | - | - | - | |
| 4 | M | 57 | Intermediate | Chronic | N/A | N/A | N/A | - | - | - | |
| 5 | M | 85 | Intermediate | Chronic | N/A | N/A | N/A | - | - | - | |
| 6 | F | 53 | Low | Chronic | N/A | N/A | N/A | - | - | - | |
| CML On treatment with TKI | 7 | M | 35 | Low | Chronic | Yes | Yes | 5 | Imatinib | 96 | - |
| 8 | F | 38 | Low | Chronic | Yes | Yes | 4 | Imatinib | 14.4 | - | |
| 9 | F | 62 | Low | Chronic | Yes | Yes | 4 | Imatinib | 24 | - | |
| 10 | F | 15 | Low | Chronic | Yes | Yes | 4.5 | Imatinib | 12 | - | |
| 11 | M | 52 | Low | Chronic | Yes | Yes | 5 | Imatinib | 168 | - | |
| 12 | F | 56 | Low | Chronic | Yes | Yes | 5 | Imatinib | 156 | - | |
| 13 | F | 52 | Intermediate | Chronic | Yes | Yes | 5 | Imatinib | 32.4 | - | |
| 14 | M | 75 | Intermediate | Chronic | Yes | Yes | 3 | Imatinib | 6 | - | |
| 15 | M | 65 | Low | Chronic | Yes | Yes | 5 | Imatinib | 15.6 | - | |
| 16 | M | 38 | Low | Chronic | Yes | Yes | 5 | Imatinib | 132 | - | |
| 17 | M | 34 | Low | Chronic | Yes | Yes | 5 | Imatinib | 40.8 | - | |
| 18 | F | 49 | Low | Chronic | Yes | Yes | 4 | Dasatinib | 30 | - | |
| 19 | F | 27 | Low | Chronic | Yes | Yes | 4.5 | Dasatinib | 9.6 | - | |
| 20 | M | 55 | Low | Chronic | Yes | Yes | 3 | Dasatinib | 30 | - | |
| 21 | F | 41 | Low | Chronic | Yes | Yes | No | Dasatinib | 1.2 | - | |
| 22 | M | 24 | Low | Chronic | Yes | Yes | 3 | Dasatinib | 84 | - | |
| 23 | F | 57 | Intermediate | Chronic | Yes | Yes | 3 | Dasatinib | 34.8 | - | |
| 24 | F | 59 | Low | Chronic | Yes | Yes | 4 | Dasatinib | 30 | - | |
| 25 | F | 57 | Low | Chronic | Yes | Yes | 3 | Dasatinib | 72 | - | |
| 26 | M | 39 | High | Chronic | Yes | Yes | No | Dasatinib | 1.2 | - | |
| 27 | F | 56 | High | Chronic | Yes | Yes | 5 | Dasatinib | 48 | - | |
| 28 | F | 55 | High | Chronic | Yes | Yes | 5 | Dasatinib | 4.8 | - | |
| 29 | M | 43 | Low | Chronic | Yes | Yes | 4.5 | Dasatinib | 12 | - | |
| 30 | M | 44 | Intermediate | Chronic | Yes | Yes | 4.5 | Dasatinib | 84 | - | |
| 31 | F | 60 | Intermediate | Chronic | Yes | Yes | 5 | Dasatinib | 12 | - | |
| 32 | F | 43 | Low | Chronic | Yes | Yes | 5 | Dasatinib | 42 | - | |
| 33 | F | 59 | Intermediate | Chronic | Yes | Yes | 5 | Dasatinib | 12 | - | |
| 34 | M | 72 | Low | Chronic | Yes | Yes | 4 | Dasatinib | 48 | - | |
| 35 | M | 26 | Low | Chronic | Yes | Yes | 5 | Dasatinib | 80.4 | - | |
| 36 | F | 35 | Low | Chronic | Yes | Yes | 4.5 | Nilotinib | 48 | - | |
| 37 | M | 35 | Low | Chronic | Yes | Yes | 5 | Nilotinib | 63.6 | - | |
| 38 | F | 43 | Low | Chronic | Yes | Yes | No | Nilotinib | 72 | - | |
| 39 | F | 59 | High | Chronic | Yes | Yes | 4 | Nilotinib | 30 | - | |
| 40 | M | 41 | Low | Chronic | Yes | Yes | 4 | Nilotinib | 79.2 | - | |
| 41 | M | 37 | Low | Chronic | Yes | Yes | 5 | Nilotinib | 60 | - | |
| 42 | F | 67 | High | Chronic | Yes | Yes | 5 | Nilotinib | 72 | - | |
| 43 | M | 47 | Low | Chronic | Yes | Yes | 5 | Nilotinib | 66 | - | |
| 44 | M | 49 | Low | Chronic | Yes | Yes | 5 | Nilotinib | 39.6 | - | |
| 45 | M | 72 | Low | Chronic | Yes | Yes | 4 | Bosutinib | 54 | - | |
| 46 | F | 54 | Low | Chronic | Yes | Yes | 4 | Bosutinib | 9.6 | - | |
| 47 | M | 29 | Low | Chronic | Yes | Yes | 3 | Bosutinib | 39.6 | - | |
| 48 | F | 62 | Low | Chronic | Yes | Yes | 3 | Bosutinib | 26.4 | - | |
| 49 | M | 29 | Low | Chronic | Yes | Yes | No | Ponatinib | UD | - | |
| 50 | F | 47 | Low | Chornic | Yes | Yes | 4 | Asciminib | 9.6 | - | |
| 51 | M | 60 | Low | Chronic | Yes | Yes | 3 | Asciminib | 1.2 | - | |
| Treatment withdrawal without CML relapse | 52 | M | 39 | Intermediate | Chronic | Yes | Yes | 4 | Imatinib | 20.4 | 12 |
| 53 | M | 49 | Low | Chronic | Yes | Yes | 4 | Imatinib | 180 | 13.2 | |
| 54 | F | 38 | Low | Chronic | Yes | Yes | 5 | Imatinib | 171.6 | 16.8 | |
| 55 | F | 55 | Low | Chronic | Yes | Yes | 5 | Imatinib | 168 | 7.2 | |
| 56 | M | 41 | Low | Chronic | Yes | Yes | 5 | Imatinib | 178.8 | 24 | |
| 57 | F | 42 | Low | Chronic | Yes | Yes | 5 | Imatinib | 182.4 | 24 | |
| 58 | F | 61 | Low | Chronic | Yes | Yes | 4 | Imatinib | 156 | 28.8 | |
| 59 | M | 71 | Low | Chronic | Yes | Yes | 5 | Imatinib | 39.6 | 7.2 | |
| 60 | M | 34 | Low | Chronic | Yes | Yes | 5 | Imatinib | 40.8 | 8.4 | |
| 61 | M | 46 | Intermediate | Chronic | Yes | Yes | 5 | Dasatinib | 54 | 13.2 | |
| 62 | M | 26 | Low | Chronic | Yes | Yes | 5 | Dasatinib | 60 | 21.6 | |
| 63 | M | 31 | Intermediate | Chronic | Yes | Yes | 5 | Dasatinib | 85.2 | 58.8 | |
| 64 | M | U/D | UD | Chronic | Yes | Yes | 4–5 | Dasatinib | UD | 24 | |
| 65 | M | 72 | Low | Chronic | Yes | Yes | 4 | Dasatinib | 48 | 8.4 | |
| 66 | M | 61 | Low | Chronic | Yes | Yes | 4 | Nilotinib | 52.8 | 54 | |
| 67 | F | 48 | Low | Chronic | Yes | Yes | 5 | Nilotinib | 15.6 | 15.6 | |
| 68 | F | 71 | Intermediate | Chronic | Yes | Yes | 5 | Nilotinib | 51.6 | 44.4 | |
| 69 | M | 74 | Intermediate | Chronic | Yes | Yes | 5 | Nilotinib | 39.6 | 40.8 | |
| 70 | M | 53 | Low | Chronic | Yes | Yes | 4.5 | Nilotinib | 43.2 | 42 | |
| 71 | F | 33 | Low | Chronic | Yes | Yes | 5 | Nilotinib | 44.4 | 40.8 | |
| 72 | F | 83 | UD | Chronic | Yes | Yes | 4–5 | Nilotinib | 24 | 6 | |
| 73 | M | 61 | UD | Chronic | Yes | Yes | 4–5 | Nilotinib | 24 | 6 | |
| 74 | M | 40 | Low | Chronic | Yes | Yes | 4–5 | Nilotinib | 60 | 12 | |
| 75 | F | 63 | Intermediate | Chronic | Yes | Yes | 4–5 | Nilotinib | 44.4 | 26.4 | |
| 76 | M | 74 | Intermediate | Chronic | Yes | Yes | 4–5 | Nilotinib | 44.4 | 26.4 | |
| 77 | M | 41 | Low | Chronic | Yes | Yes | 5 | Nilotinib | 79.2 | 9.6 | |
| 78 | M | 47 | Low | Chronic | Yes | Yes | 5 | Nilotinib | 66 | 27.6 | |
| CML relapsed | 79 | F | 61 | Intermediate | Chronic | Yes | Yes | No | Imatinib | 40.8 | 14.4 |
| 80 | M | 35 | Low | Chronic | Yes | Yes | No | Imatinib | 39.6 | 4.8 | |
| 81 | M | 71 | Low | Chronic | Yes | Yes | No | Imatinib | 39.6 | 9.6 | |
| 82 | F | 28 | Low | Chronic | Yes | Yes | 4 | Imatinib | 60 | 8.4 | |
| 83 | M | 48 | Low | Chronic | Yes | Yes | No | Dasatinib | 43.2 | 3.6 | |
| 84 | M | 26 | Low | Chronic | Yes | Yes | No | Dasatinib | 80.4 | 3.6 | |
| 85 | F | 25 | Low | Chronic | Yes | Yes | 4 | Dasatinib | 60 | 7.2 | |
| 86 | F | 36 | Low | Chronic | Yes | Yes | 4.5 | Dasatinib | 60 | 4.8 | |
| 87 | F | 49 | Low | Chronic | Yes | Yes | 4 | Dasatinib | 180 | 2.4 | |
| 88 | M | 45 | Low | Chronic | Yes | Yes | No | Nilotinib | 228 | UD | |
| 89 | M | 22 | Low | Chronic | Yes | Yes | No | Nilotinib | 50.4 | 3.6 | |
| 90 | M | 57 | Intermediate | Chronic | Yes | Yes | No | Nilotinib | 48 | 6 | |
| 91 | F | 38 | Low | Chronic | Yes | Yes | 4.5 | Nilotinib | 72 | 3.6 | |
| 92 | F | 27 | Low | Chronic | Yes | No | No | Bosutinib | 48 | 1.2 | |
| 93 | F | 57 | Low | Chronic | No | No | No | Bosutinib | UD | 7.2 |